8-K: Seres Therapeutics Reports Positive Clinical Data and Strategic Shift Following Asset Sale

Seres Therapeutics announced positive Phase 1b clinical results for SER-155, a reduction in bloodstream infections, and a strategic focus on its pipeline after the sale of VOWST.

Summary

• Seres Therapeutics reported third quarter 2024 financial results and provided business updates, highlighting a transformational quarter.
• The company completed the sale of its VOWST business to Nestl Health Science for $175 million upfront, with potential for up to $275 million in future milestone payments.
• Seres received $175 million upfront, less approximately $20 million in net obligations, and expects to receive $75 million in installment payments in 2025.
• The company's SER-155 Phase 1b study showed a 77% relative risk reduction in bloodstream infections compared to placebo in patients undergoing allogeneic hematopoietic stem cell transplants (allo-HSCT).
• SER-155 also demonstrated a significant reduction in systemic antibiotic exposure and a lower incidence of febrile neutropenia.
• Seres has requested Breakthrough Therapy and Qualified Infectious Disease Product (QIDP) designations for SER-155 from the FDA, with feedback expected by the end of 2024.
• The company is planning for a potential single registration study for SER-155 in allo-HSCT and intends to engage with the FDA in the first quarter of 2025.
• Seres is seeking a strategic partner to support the development of SER-155 and expand its application to other patient populations.
• The company reported a net loss from continuing operations of $51 million for the third quarter of 2024, compared to a $41 million loss in the same period of 2023.
• This loss includes a $23.4 million loss associated with the extinguishment of the Oaktree debt.
• Research and development expenses decreased to $16.5 million in Q3 2024 from $25.2 million in Q3 2023.
• General and administrative expenses decreased to $12.7 million in Q3 2024 from $19.4 million in Q3 2023.
• Net income from discontinued operations was $139.8 million for Q3 2024, primarily due to the gain on the sale of the VOWST business.
• As of September 30, 2024, Seres had $66.8 million in cash and cash equivalents.
• The company expects to fund operations into the fourth quarter of 2025 based on existing cash, projected installment payments, and current operating plans.

Sentiment

Score: 8

Explanation: The document presents a positive outlook due to the strong clinical results of SER-155 and the improved financial position following the VOWST sale. However, there are risks associated with Nasdaq compliance and the need for a strategic partnership.

Positives

• The sale of the VOWST business has provided a significant cash infusion and strengthened the company's financial position.
• The positive Phase 1b clinical results for SER-155 demonstrate a strong potential for reducing bloodstream infections and related complications.
• The company has a clear strategic focus on SER-155 and other pipeline programs.
• Seres has a streamlined organization with no outstanding debt and a lower cash burn rate.
• The company expects to fund operations into the fourth quarter of 2025.
• The company is actively seeking a partner to maximize the SER-155 opportunity.
• The company has a validated platform with the previous approval of VOWST.

Negatives

• The company reported a net loss from continuing operations of $51 million for the third quarter of 2024.
• The company's stock price has fallen below the $1.00 minimum bid price requirement for continued listing on The Nasdaq Global Select Market.
• There is no assurance that the company will be able to regain compliance with the Nasdaq listing requirements.
• The company is reliant on future milestone payments from the VOWST sale.
• The company is reliant on securing a strategic partnership for SER-155 development.

Risks

• The company may not be able to regain compliance with the Nasdaq minimum bid price requirement, potentially leading to delisting.
• There is no guarantee that the company will secure a strategic partnership for SER-155 development.
• The company is dependent on receiving future milestone payments from the VOWST sale.
• The company may face challenges in expanding the application of SER-155 to other patient populations.
• The company may not be able to realize the anticipated benefits of the VOWST sale.
• The company is subject to risks associated with the development of novel therapeutics.

Future Outlook

Seres expects to fund operations into the fourth quarter of 2025 based on existing cash, projected installment payments, and current operating plans. The company is focused on advancing SER-155 and other pipeline programs, and is seeking a strategic partner to support SER-155 development. They also intend to engage with the FDA regarding a potential single registration study for SER-155.

Management Comments

• Eric Shaff, President and Chief Executive Officer of Seres, stated that this quarter has been transformational for Seres, highlighted by positive SER-155 clinical results and the sale of VOWST.
• Mr. Shaff elaborated that with SER-155 as their primary focus, they have the opportunity to expand beyond allo-HSCT to other patient populations.
• Management believes that a product providing similar efficacy to what they observed in their SER-155 studies would be transformational in the management of allo-HSCT patients.

Industry Context

This announcement comes at a time when there is a growing focus on microbiome-based therapeutics and the need for effective treatments for infections in vulnerable patient populations. The positive results for SER-155 and the strategic shift towards this program position Seres as a key player in this space. The sale of VOWST allows Seres to focus on its pipeline and potentially expand into new markets.

Comparison to Industry Standards

• The 77% relative risk reduction in bloodstream infections with SER-155 is a significant result compared to standard of care in allo-HSCT, where infection rates are high and mortality is a major concern.
• The company's previous success with VOWST, the first FDA-approved oral live microbiome therapeutic, provides a strong foundation for the development of SER-155.
• The company's approach of using cultivated live biotherapeutics, rather than donor-sourced material, is a differentiating factor compared to some other microbiome companies.
• The company's focus on preventing infections in medically vulnerable populations aligns with a growing need in the healthcare industry, as evidenced by the increasing use of prophylactic treatments like Prevymis for viral infections.
• The company's market research indicates that a product with similar efficacy to SER-155 would be rapidly adopted as standard practice, suggesting a strong commercial potential.

Related Party Transactions

• The sale of the VOWST business to Socit des Produits Nestl S.A (SPN) is a related party transaction.
• There are accrued liabilities due to SPN related to the VOWST sale.

Stakeholder Impact

• Shareholders will benefit from the improved financial position and the potential for SER-155 to become a successful product.
• Employees may experience changes due to the restructuring and strategic shift.
• Patients may benefit from the development of SER-155, which has the potential to reduce the risk of serious infections.
• The sale of VOWST may impact customers and suppliers of that business.

Next Steps

• Seres will engage with the FDA in the first quarter of 2025 to discuss the clinical study results and future study design for SER-155.
• The company will continue to seek a strategic partner to support the development of SER-155.
• Seres will evaluate SER-155 in additional patient populations with high risk of serious bacterial infections.
• The company will advance SER-147 towards IND readiness.
• Seres will monitor the closing bid price of its common stock and may consider actions to regain compliance with Nasdaq listing requirements, including a potential reverse stock split.

Key Dates

Keywords

SER-155, VOWST, live biotherapeutics, bloodstream infections, allo-HSCT, microbiome, Nestl Health Science, strategic partnership, FDA, clinical trial, bacterial infections, financial results